Posts by Steven Chervenick
Orphan Drug Status Given to New Treatment for Mesothelioma
A new treatment for mesothelioma was recently given orphan drug status by the United States FDA. The company given orphan drug status is known as Avenge Bio, which is a biotechnology company working to create a new immunotherapy treatment regimen. It announced that it was given orphan drug status back in June. People are being…
Read MoreGenetic Testing for Mesothelioma
A new study is showing that running genetic tests on mesothelioma patients could be useful. The study was conducted at the University of Chicago and University of Wisconsin. While the main cause of mesothelioma is asbestos, genetic mutations can also influence people getting mesothelioma. Doctors do not usually test mesothelioma patients’ genes, but researchers believe…
Read MoreBiomarkers Could be Used to Monitor Mesothelioma Patients
Researchers from Türkiye believe that biomarkers in the blood can help determine if patients are responding well to their treatment. Biomarkers are molecules that can let doctors know what is happening in the body. Even a small number of biomarkers could potentially help point doctors to progress being made in a patient. The researchers were…
Read MoreNew Rules Regarding Reporting of Asbestos
The U.S. Environmental Protection Agency announced its final rule requiring comprehensive reporting of asbestos. The rule requires that importers and manufacturers of asbestos related products report information including use and exposure information from the past four years. The new rule was issued under the Toxic Substances Control Act. The reporting rule is due to the…
Read MoreDecitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Primary Outcome Measures To determine stabilization or disease improvement rates in participants with early-stage mesotheliomas arising in the context of BAP1 CPDS following decitabine/cedazuridine treatment Secondary Outcome Measures To evaluate the safety of decitabine/cedazuridine To determine PFS in participants receiving decitabine/cedazuridine Inclusion Criteria Participants with history of germline BRCA1-Associated Protein-1 (BAP1) mutations. Histologically confirmed by…
Read MorePARP Inhibitors Could Soon Help Mesothelioma Patients
There is a new treatment involving PARP inhibitors that could potentially benefit mesothelioma patients. PARP stands for Poly (ADP-ribose) polymerase. PARP is typically involved in repairing damaged DNA in cells. It can be useful against side effects from chemotherapy by repairing damaged tumor cells, which helps tumors to continue growing. The goal would be to…
Read MoreMarine Bacteria Could Potentially Detoxify Asbestos
There may be a new way to detoxify asbestos. Researchers at the University of Pennsylvania’s Department of Earth and Environmental Science are using bacteria from extreme marine environments. They are using a technique called bioremediation, which is a form of biotechnology that uses living organisms to remove toxins or contaminants from the environment. This technique…
Read MoreLawyer for Johnson & Johnson Must Stop Making Unsubstantiated Claims About Potential Settlement
A lawyer for Johnson & Johnson must stop making unsubstantiated claims about support from plaintiffs for an $8.9 billion settlement for talc victims without backing up the claims. The lawyer was ordered to halt statements after a late June hearing in Trenton, New Jersey. Plaintiffs’ attorneys investigated the claims that Johnson & Johnson secured commitments…
Read MoreStudy of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Primary Outcome Measures Objective Response Rate (ORR) defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. Up to 36 months Secondary Outcome Measures Progression Free Survival (PFS) defined as the time between the…
Read MoreCRS-HIPEC for the Treatment of Peritoneal Mesothelioma
Researchers are studying the effectiveness of a multimodal treatment for peritoneal mesothelioma. The therapy involves cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC. Peritoneal mesothelioma is cancer of the abdominal lining. It is caused by inhaled or ingested asbestos fibers that travel to the lining of the abdomen. Over time, these fibers cause DNA changes…
Read More